Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > AGN Patent Application News Summary

View:

Post by StockHawk1 on Apr 17, 2023 6:54pm

AGN Patent Application News Summary

Algernon Pharmaceuticals (AGN.c AGNPF) closed in the green today after announcing it received a Notice of Allowance from the US Patent and Trademark Office for its patent application for its lead chronic kidney disease (CKD) drug Repirinast.

Repirinast has shown promising results in reducing hepatic fibrosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH).

Repirinast is also being investigated as a treatment for CKD, as patients with NAFLD have an increased risk of developing CKD.

Repirinast works by binding to receptors on mast cells to prevent their degranulation, which AGN believes could help prevent fibrosis in multiple organs, including the kidneys and the liver.

More here:

https://www.globenewswire.com/news-release/2023/04/17/2647769/0/en/Algernon-Pharmaceuticals-Announces-Notice-of-Allowance-for-Method-of-Use-U-S-Patent-Application.html

203